Showing results (101-110 of 241) with videos related to

Sort By:
Pageof 25
Scientific Reports|November 17, 2021
A phase I study of the WT2725 dosing emulsion in patients with advanced malignanciesSiqing Fu, David E Piccioni, Hongtao Liu, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaTimothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Anticancer Research|April 30, 2014
Outcomes of patients with metastatic cervical cancer in a phase I clinical trials programMing-Mo Hou, Xiaochun Liu, Jennifer Wheler, et al.
Investigational New Drugs|June 13, 2013
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Oncotarget|July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trialsIshwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Cancer|April 8, 2011
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerSiqing Fu, Wei Hu, Revathy Iyer, et al.
Pageof 25